Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Virol J ; 10: 343, 2013 Nov 20.
Article in English | MEDLINE | ID: mdl-24252426

ABSTRACT

BACKGROUND: Human papillomavirus (HPV) is associated with different malignancies but its role in the pathogenesis of ovarian cancer is controversial. This study investigated the prevalence, genotyping and physical state of HPV in ovarian cancer Saudi patients. METHODS: Hundred formalin fixed paraffin embedded (FFPE) ovarian carcinoma tissues and their normal adjacent tissues (NAT) were included in the study. HPV was detected by nested polymerase chain reaction (PCR) using degenerated HPVL1 consensus primer pairs MY09/MY11 and GP5+/GP6 + to amplify a broad spectrum of HPV genotypes in a single reaction. The HPV positive samples were further genotyped using DNA sequencing. The physical state of the virus was identified using Amplification of Papillomavirus Oncogene Transcripts (APOT) assay in the samples positive for HPV16 and/or HPV18. RESULTS: High percentage of HPV (42%) was observed in ovarian carcinoma compared to 8% in the NAT. The high-risk HPV types 16, 18 and 45 were highly associated with the advanced stages of tumor, while low-risk types 6 and 11 were present in NAT. In malignant tissues, HPV-16 was the most predominant genotype followed by HPV-18 and -45. The percentage of viral integration into the host genome was significantly high (61.1%) compared to 38.9% episomal in HPV positive tumors tissues. In HPV18 genotype the percentage of viral integration was 54.5% compared to 45.5% episomal. CONCLUSION: The high risk HPV genotypes in ovarian cancer may indicate its role in ovarian carcinogenesis. The HPV vaccination is highly recommended to reduce this type of cancer.


Subject(s)
Ovarian Neoplasms/virology , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Virus Integration , Adult , Aged , DNA Primers/genetics , Female , Genotype , Humans , Middle Aged , Ovarian Neoplasms/etiology , Papillomaviridae/physiology , Papillomavirus Infections/complications , Polymerase Chain Reaction , Prevalence , Saudi Arabia/epidemiology , Sequence Analysis, DNA
2.
BMC Complement Altern Med ; 13: 136, 2013 Jun 17.
Article in English | MEDLINE | ID: mdl-23773725

ABSTRACT

BACKGROUND: High-cholesterol diet (HCD) increases the oxidative stress in different tissues leading to many diseases. Rutin (RT) is a natural flavonoid (vitamin p), which possesses an antioxidant activity with protective potential. The present study aimed to examine the potential effects of rutin on hypercholesterolemia-induced hepatotoxicity in rat. METHODS: Male Wistar rats were divided into four groups: GI) control (Rat chow), GII) Rutin (0.2% in rat chow), GIII) HCD (1% cholesterol and 0.5% cholic acid in rat chow) and GIV) rutin (0.2%) + HCD. RESULTS: Rutin in combination with HCD induced a significant protective effect against the hepatotoxicity by reducing the plasma level of alanine transaminase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), and low-density lipoprotein (LDL). The HCD (GII) showed a decrease in glutathione peroxidase (GPx), glutathione reductase (GR) and increase in glutathione S transferase α (GSTα), sulfiredoxin-1(Srx1), glutamate-cysteine ligase (GCL) and paraoxonase-1(PON-1) genes expression levels. CONCLUSION: Treatment with rutin reversed all the altered genes induced by HCD nearly to the control levels. The present study concluded that the HCD feedings altered the expression levels of some genes involved in the oxidative stress pathway resulting in DNA damage and hepatotoxicity. Rutin have a hepatoprotective effect through the mechanism of enhancing the antioxidant effect via amelioration of oxidative stress genes.


Subject(s)
Antioxidants/metabolism , Hypercholesterolemia/drug therapy , Hypercholesterolemia/enzymology , Protective Agents/administration & dosage , Rutin/administration & dosage , Alanine Transaminase/genetics , Alanine Transaminase/metabolism , Animals , Aryldialkylphosphatase/genetics , Aryldialkylphosphatase/metabolism , Aspartate Aminotransferases/genetics , Aspartate Aminotransferases/metabolism , Gene Expression/drug effects , Glutathione Peroxidase/genetics , Glutathione Peroxidase/metabolism , Glutathione Transferase/genetics , Glutathione Transferase/metabolism , Humans , Hypercholesterolemia/genetics , Isoenzymes/genetics , Isoenzymes/metabolism , Lipoproteins, LDL/metabolism , Male , Oxidative Stress/drug effects , Rats , Rats, Wistar
3.
Oxid Med Cell Longev ; 2012: 696704, 2012.
Article in English | MEDLINE | ID: mdl-23213347

ABSTRACT

It is well documented that ifosfamide (IFO) therapy is associated with sever nephropathy in the form of Fanconi syndrome. Although oxidative stress has been reported as a major player in IFO-induced Fanconi syndrome, no mechanism for this effect has been ascertained. Therefore, this study has been initiated to investigate, on gene expression level, the mechanism of IFO-induce nephrotoxicity and those whereby carnitine supplementation attenuates this serious side effect of IFO. To achieve the ultimate goals of this study, adult male rats were assigned to one of four treatment groups, namely, control, L-carnitine, IFO, and IFO plus L-carnitine. Administration of IFO for 5 days significantly increased serum creatinine, blood urea nitrogen (BUN), and total nitrate/nitrite (NOx) production in kidney tissues. In addition, IFO significantly increased mRNA expression of inducible nitric oxide synthase (iNOS), caspase-9, and caspase-3 and significantly decreased expression of glutathione peroxides (GPx), catalase (CAT), and Bcl2 in kidney tissues. Administration of L-carnitine to IFO-treated rats resulted in a complete reversal of the all biochemical and gene expression changes, induced by IFO, to the control values. Data from this study suggest that L-carnitine prevents the development of IFO-induced nephrotoxicity via downregulation of oxidative and nitrosative apoptotic signaling in kidney tissues.


Subject(s)
Apoptosis/drug effects , Carnitine/pharmacology , Down-Regulation/drug effects , Fanconi Syndrome/metabolism , Fanconi Syndrome/pathology , Signal Transduction/drug effects , Animals , Blood Urea Nitrogen , Caspases/genetics , Caspases/metabolism , Catalase/genetics , Catalase/metabolism , Creatinine/blood , Disease Models, Animal , Fanconi Syndrome/blood , Gene Expression Regulation, Enzymologic/drug effects , Glutathione Peroxidase/genetics , Glutathione Peroxidase/metabolism , Ifosfamide/chemistry , Kidney/drug effects , Kidney/enzymology , Kidney/pathology , Male , Nitrates/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Nitrites/metabolism , Nitrosation/drug effects , Oxidation-Reduction/drug effects , Rats , Rats, Wistar
4.
Asian Pac J Cancer Prev ; 13(2): 591-8, 2012.
Article in English | MEDLINE | ID: mdl-22524830

ABSTRACT

AIM AND BACKGROUND: MicroRNAs (miRNAs) are a class of naturally occurring small noncoding RNAs that regulate gene expression, cell growth, differentiation and apoptosis by targeting mRNAs for translational repression or cleavage. The present study was conducted to study miRNAs in Egyptian breast cancer (BC) and their relation to metastasis, tumor invasion and apoptosis in addition to their association with the ER and PR statuses. METHODS: Real Time RT-PCR was performed to identify the miRNA expression level of eight miRNAs and eight metastatic-related genes in 40 breast cancer samples and their adjacent non-neoplastic tissues. The expression levels of each miRNA relative to U6 RNA were determined. Also, miRNA expression profiles of the BC and their corresponding ANT were evaluated. RESULTS: The BC patients showed an up-regulation in miRNAs (mir-155, mir-10, mir-21 and mir-373) with an upregulation in MMP2, MMp9 and VEGF genes. We found down regulation in mir-17p, mir-126, mir-335, mir-30b and also TIMP3, TMP1 and PDCD4 genes in the cancer tissue compared to the adjacent non-neoplastic tissues. Mir -10b, mir -21, mir-155 and mir373 and the metastatic genes MMP2, MMP9 and VEGF were significantly associated with an increase in tumor size (P<0.05). No significant difference was observed between any of the studied miRNAs regarding lymph node metastasis. Mir-21 was significantly over-expressed in ER-/PR- cases. CONCLUSION: Specific miRNAs (mir-10, mir-21, mir-155, mir-373, mir-30b, mir-126, mir-17p, mir-335) are associated with tumor metastasis and other clinical characteristics for BC, facilitating identification of individuals who are at risk.


Subject(s)
Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , Breast Neoplasms/secondary , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Breast/metabolism , Breast/pathology , Egypt , Female , Gene Expression Profiling , Humans , Lymphatic Metastasis , Neoplasm Grading , Oligonucleotide Array Sequence Analysis , Prognosis
5.
Eur J Pharmacol ; 640(1-3): 143-9, 2010 Aug 25.
Article in English | MEDLINE | ID: mdl-20470772

ABSTRACT

This study examined whether doxorubicin therapy alters the expression of heart fatty acid binding protein (H-FABP) and organic cation/carnitine transporter (OCTN2) genes in cardiac tissues, and if so, whether these alterations contributes to doxorubicin-induced cardiotoxicity. Male Wistar albino rats were divided into six groups: group 1 rats were given daily intraperitoneal (i.p.) injections of normal saline for 10 consecutive days; groups 2, 3 and 4 rats were injected every other day with doxorubicin (3 mg/kg, i.p.), to obtain treatments with cumulative doses of 6, 12, and 18 mg/kg. Rats in the fifth group were injected with L-carnitine (200 mg/kg, i.p.) for 10 consecutive days. Animals in the sixth group received doxorubicin (18 mg/kg) and L-carnitine (200 mg/kg). Treatment with doxorubicin resulted in a significant and dose-dependent decrease in H-FABP and OCTN2 mRNA expression, total carnitine and ATP in cardiac tissues and a significant increase in cardiac enzymes. Moreover, doxorubicin treatment showed significant and dose-dependent increase in the expression of apoptotic genes namely P53 and CD95. Interestingly, carnitine supplementation restored doxorubicin-induced inhibition of gene expression of H-FABP and OCTN2, decrease in myocardial carnitine and ATP to the control values. In conclusion, data from this study suggest that: chronic doxorubicin therapy decreased the expression of H-FABP and OCTN2 mRNA expression in cardiac tissues. The progressive increase in cardiotoxicity enzymatic indices and the decrease in H-FABP and OCTN2 expression may point to the possible contribution of H-FABP and OCTN2 as a mechanism during development of doxorubicin cardiotoxicity.


Subject(s)
Cardiomyopathies/chemically induced , Cardiomyopathies/genetics , Doxorubicin/toxicity , Fatty Acid-Binding Proteins/genetics , Gene Expression Regulation/drug effects , Heart/drug effects , Organic Cation Transport Proteins/genetics , Animals , Cardiotoxins/toxicity , Disease Models, Animal , Dose-Response Relationship, Drug , Male , Myocardium/metabolism , Rats , Rats, Wistar , Solute Carrier Family 22 Member 5 , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...